EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Nandita Nadig, Adarsh Bhimraj iD, Kelly Cawcutt, Kathleen Chiotos iD, Amy L Dzierba, Arthur Y Kim, Greg S Martin, Jeffrey C Pearson, Amy Hirsch Shumaker, Lindsey R Baden, Roger Bedimo iD, Vincent Chi-Chung Cheng und 17 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf235 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Nandita Nadig und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antiviral Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Infectious Diseases Society of America, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentAntiviral AgentsAntibodies, Monoclonal, HumanizedHumansSARS-CoV-2COVID-19United StatesAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19SARS-CoV-2guidelinemonoclonal antibodyvilobelimab

Substanzen

Antiviral AgentsAntibodies, Monoclonal, HumanizedbamlanivimabAntibodies, Neutralizing

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Adarsh Bhimraj, Kathleen Chiotos, Roger Bedimo, David V Glidden, Laura Riley, Shmuel Shoham, Pablo Tebas

Förderung

  • NIH HHS
  • Infectious Diseases Society of America
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., Li, J. Z., MacBrayne, C., …, & Gandhi, R. T. (2026). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf235

Vancouver

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf235

BibTeX
@article{Nadig2026,
  author = {Nadig, Nandita and Bhimraj, Adarsh and Cawcutt, Kelly and Chiotos, Kathleen and Dzierba, Amy L and Kim, Arthur Y and Martin, Greg S and Pearson, Jeffrey C and Shumaker, Amy Hirsch and Baden, Lindsey R and Bedimo, Roger and Cheng, Vincent Chi-Chung and Chew, Kara W and Daar, Eric S and Glidden, David V and Hardy, Erica J and Johnson, Steven and Li, Jonathan Z and MacBrayne, Christine and Nakamura, Mari M and Riley, Laura and Shafer, Robert W and Shoham, Shmuel and Tebas, Pablo and Tien, Phyllis C and Loveless, Jennifer and Falck-Ytter, Yngve and Morgan, Rebecca L and Gandhi, Rajesh T},
  title = {2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf235}
}
Kostenlos starten →